What sector does Biogen belong to?

Biogen operates in the Health Care sector, specifically the Biotechnology industry, and is listed on the US markets.

What is the current share price of BIIB?

As of the latest available quote, BIIB traded at $217.15. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of BIIB?

Biogen has a price-to-earnings (P/E) ratio of about 38.64. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of BIIB?

The market capitalisation of Biogen is approximately $31.94B.

Is Biogen profitable?

For its latest reported financial year, Biogen recorded a net profit margin of about 13.07%.

Does BIIB pay a dividend?

Biogen does not currently show a dividend yield in our data.

What is the return on equity (ROE) of BIIB?

Biogen has a return on equity (ROE) of about 8.74%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of BIIB?

Over the past 52 weeks, BIIB has traded between a low of $135.39 and a high of $225.80.

Biogen

BIIB US Health Care Biotechnology

S&P 500

$217.15

+0.80%

Delayed · cached 15 min

Fair value analysis

BIIB

Biogen

$217.15

Close used for this calculation

$182.18Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

44/100

Profitability10/25

Returns7/25

Balance Sheet21/25

Efficiency6/25

Growth1/25

Average

Quality radar

Consensus fair value

$182.18

Above FV

▼ -16.1% against the close used

Model range $26.90 – $261.32

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$26.90Fair value$182.18Bull$261.32

FairClose

52-week traded range

52W low $135.6752W high $224.51

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Biogen closed at $217.15, 19.2% above the consensus fair value of $182.18 drawn from 8 valuation models.

Financial DNA score 44/100 — Average. P/E of 24.7x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$261.32

+20.3%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=8%, r=10%, tg=3%, n=10yr

Graham Number

$140.36

-35.4%

√(22.5 × EPS × BVPS)

EPS=8.79, BVPS=99.61 · outside Graham range (P/E 24.7, P/B 2.2) — asset-light, treat as a rough floor

P/E Fair Value

$175.80

-19.0%

EPS × 20x (sector P/E)

EPS=8.79, Sector P/E=20x

Peter Lynch (PEG)

$26.90

-87.6%

EPS × Growth% (PEG = 1 is fair)

EPS=8.79, g=3.1%

EV/EBITDA

$136.56

-37.1%

(EBITDA × 10x − Net Debt) ÷ Shares

EBITDA=2.34B

Book Value (P/B)

$81.68

-62.4%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=99.61, ROE=8.7%, g=3%, r=10%

Reverse DCF

$217.15

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 10% | Historical: -3.1%

Margin of Safety

$144.37

-33.5%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=192.49, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer